Cargando…

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response

PURPOSE: Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation of preliminary anti-tumor efficacy. PATIENTS AND METHODS: Nine patients fulfilling the set criteria were enrolled. Eight had recurrent glioblastoma and one gliosarcoma. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Aiken, Robert, Axelson, Magnus, Harmenberg, Johan, Klockare, Maria, Larsson, Olle, Wassberg, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655304/
https://www.ncbi.nlm.nih.gov/pubmed/29113409
http://dx.doi.org/10.18632/oncotarget.20662